#France #Frankfurt #Essential Tremor #Insightec #Exablate Prime

Insightec's Landmark Achievement in France

Introduction

On March 3, 2026, Insightec, an innovative healthcare company based in Israel, made headlines by announcing that France has recognized national reimbursement for its advanced MR-guided focused ultrasound treatment for essential tremor. This significant development allows hospitals across France to offer incisionless therapy for patients who do not respond to traditional medication. With more than 380,000 people affected by essential tremor in France, the need for effective treatments is paramount.

The New Reimbursement Framework

The decision for national reimbursement was officially published in the Journal Officiel de la République Française and is effective immediately. Under this new framework, patients suffering from moderate to severe essential tremor, who have not found relief through medication, are eligible for unilateral MR-guided focused ultrasound therapy. This therapy leverages continuous MRI guidance to accurately target the brain region responsible for tremors, providing a non-invasive treatment option.

The Haute Autorité de Santé (HAS), which previously assessed the clinical benefits of this technology, played a crucial role in this achievement by emphasizing the importance of informed consent and patient registration to track long-term outcomes. Insightec is collaborating with hospitals and patient associations to ensure thorough implementation and accessibility for patients throughout France.

The Impact on Patients

Annie Le Brun, President of APTES—the Association of People Affected by Essential Tremor—expressed optimism about this development. She noted that many individuals suffering from essential tremor are medication-refractory, showcasing the urgency for innovative treatments. With approximately 1,500 new patients annually lacking effective relief, the implementation of this therapy represents hope for many.

Dr. Maurice R. Ferré, the CEO and Chairman of Insightec, highlighted the import of this milestone, stating that it enables hospitals to provide incisionless, MR-guided focused ultrasound for those living with debilitating tremors. This initiative is viewed as a significant stride towards enhancing patient-centered care, providing an alternative for surgical intervention through a safer, non-invasive route.

Technology Behind the Treatment

Insightec’s Exablate Prime, the next-generation focused ultrasound system, has been pivotal in the treatment of essential tremor. Utilizing focused ultrasound energy, the system disrupts abnormal brain signaling responsible for tremors, leading to improved quality of life for patients. By avoiding incisions, the system affords patients a quicker recovery and less risk of complications.

Prominent figures in neurosurgery, including Prof. Jean Régis from La Timone University Hospital, endorsed the treatment's establishment as a neurosurgical procedure without incisions. He emphasized that national access for this therapy is essential, ensuring patients can fully exploit surgical options available for managing essential tremor.

Conclusion

Insightec’s commitment to fostering innovative healthcare solutions has culminated in a transformative moment for individuals with essential tremor in France. With national reimbursement now in place, the door opens for hospitals to deliver vital, incisionless treatment options to countless patients. This development not only raises awareness for essential tremor but also represents progress in the movement towards modern, patient-oriented healthcare solutions.

Insightec continues to push boundaries, aiming to expand the applications of focused ultrasound technology in treating various neurological conditions. With a growing presence across Europe and a focus on collaboration with medical institutions, the future looks promising for patients affected by movement disorders.

For more information on Insightec and its innovative treatments, visit Insightec's website.